Strategic Vision: A Global Pharma Company
Optimizing R&D investment
Invested INR 14 bn or 8.7% of sales on R&D in FY22at 7 R&D sites globally
R&D spend
Generics filings Pipeline
IR&D Cost (INR bn)
R&D as % of Sales
25.0
13.5%
14%
457 cumulative filings
11.9%
20.0
10.5%
12%
10.3%
9.6%
8.7%
10%
15.0
160 pending
8%
23.1
approval
10.0
6%
18.5
15.0
15.5
14.3
14.0
4%
5.0
2%
53 First to files
0.0
0%
(21 excl. FTFs)
FY 17
FY 18
FY 19
FY 20
FY 21
FY 22
Optimizing R&D spend
Targeting >US$ 188 bn brand + generics sales, of which
•
O
Filed products target US$ 117.2 bn
Products in development target US$ 70.7 bn of which complex categories account for ~85%
53 First-to-Files (FTF) filings including 21 exclusive FTF opportunities targeting US$ 5.9 bn
IQVIA MAT Mar 2022/ Company reported sales
LUPIN
20
20View entire presentation